APC: APC sends follow up to CA BOP

Journalistic malpractice

This piece is appalling – both the bias and error in the article itself AND that Pharmacy Times would take a swipe at a legitimate pharmacy practice like pharmacy compounding. read more →
Let’s get together

APC may soon be coming to a city near you — and we’d love to meet up. We’ll be in the Tampa/St. Pete area on June 12 for our next CompoundED UpDATE — part of a series of regional meetings made possible by a grant from PCCA. read more →
NABP gets it right in their latest report

Drugmakers, newsmedia, and even regulators have been wrongly conflating legitimate compounding of GLP-1s with illegal online drug sales. In their latest RogueRx Activity Report, NABP doesn’t make that mistake. read more →
Major new study: Hormone therapy benefits outweigh risks in menopause

A recent study published in JAMA suggests that the benefits of hormone therapy outweigh the risks for treating menopause symptoms, particularly among women under 60. read more →
Mass confusion: Our letter

This week, APC submitted a comment letter to the Massachusetts Board of Pharmacy about two issues on which the Board recently expressed concern. read more →
APC to regulators: The stability study backlog is real

This week, APC wrote to state boards of pharmacy and FDA to make them aware of delays in completing stability studies as USP 797 is enforced across the country. read more →

September 15, 2023

APC sends follow up to CA BOP

Earlier this week, APC sent a letter to the California Board of Pharmacy requesting clarification on their Draft Compounding Policy statement on USP <797> sterile compounding standards, noting that the confusing language regarding the Board’s intentions and expectations may be difficult for compounders to understand and implement.

Find and Join

News Logo

More News

» More APC News «

Fagron Ad

PCCA Ad

Medisca Ad

TopiClick Ad

APC sends follow up to CA BOP